At the news
? NEUTRALIMPACT 5/10 PRESS-RELEASE filed Mar 12, 2026 at 16:05 ET
Oruka Therapeutics reported fourth quarter and full year 2025 financial results, highlighted by $479.6 million in cash and advancement of its two lead programs: ORKA-001 and ORKA-002. Enrollment in the EVERLAST-A trial for ORKA-001 completed ahead of schedule, with 16-week data now expected in 2Q 2026. The Phase 2 ORCA-SURGE trial for ORKA-002 in psoriasis has been initiated, with data anticipated in 2027.
- Cash, cash equivalents, and marketable securities totaled $479.6 million as of December 31, 2025.
- Net loss was $29.6 million in Q4 2025 and $105.4 million for the full year 2025.
- R&D expenses were $27.6 million in Q4 2025 and $100.6 million for the full year 2025.
- Enrollment in EVERLAST-A (ORKA-001) completed in December 2025; 16-week data expected in 2Q 2026.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access